MarkWide Research

Sale!

Cystic Fibrosis Drug Market Analysis 2022-2030

Published Date: June, 2022
No of Pages: 169
Delivery Format: PDF+ Excel

$2,950.00

Cystic Fibrosis Drug Market Overview

The cystic fibrosis drug market was estimated at USD 3.56 billion in xxx. The rising rate of Cystic Fibrosis (CF) coupled with the growing rate of treatment is among the significant reasons that will drive the demand for therapies for cystic fibrillation in the coming years. Furthermore, there is a rise in R&D funding from both public and private organizations as well as a rise in initiatives being undertaken by non-profit organizations, and the existence of favorable reimbursement policies are just a few of the critical elements that are expected to propel the market over the next few years.

An increase in drug combinations in the pipeline of major players is among the major factors predicted to drive Cystic fibrosis drug market. Additionally, an increase in the number of clinical trials that increase the number of patients it targets in conjunction with its existing drug portfolio is one of the factors driving the cystic fibrosis drug market. A growing number of R&D activities will likely drive this market’s growth. Some pipelined medications include (VX-445 + tezacaftor plus IVACAFTOR) PTI-428; QR-010, AZD-5634 POL-6014; and QR-010.

Various non-profit organizations like Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, Cystic Fibrosis Canada, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association are always involved in initiatives related to CF, the main reasons for the increasing demand of Cystic fibrosis drug market. These organizations are investing massive sums of money in finding different treatments for CF and funding the key players’ research and development activities.

cystic fibrosis drug market

Get more information on this report : Download Free Sample Pages

Drug Class Information of Cystic fibrosis drug market

The market is divided into pancreatic enzyme supplement mucolytics and bronchodilators, as well as CFTR modulators according to the class of drugs. The most crucial consideration in CF treatments in maintaining lung function while reducing respiratory infections and clearing the mucus from the airways, coordinating the nutritional therapy, and preventing complications. Kalydeco was the initial CFTR modulator drug released at the end of 2012 U.S. In 2014 it was the sole CFTR modifiable drug on the market.

  • This drug class is anticipated to be the fastest-growing sector due to the increased quantity of drugs being developed. The CFTR modulators drug combinations currently in development include:
    • VX-445+tezacaftor+ivacaftor
    • VX-659+tezacaftor+ivacaftor
    • VX-152+tezacaftor+ivacaftor
    • VX-440+tezacaftor+ivacaftor
    • Tezacaftor (VX-661)+Ivacaftor
    • PTI-428, QR-010
    • CTP-656 (Deuterated ivacaftor)
    • FDL 169
    • GLPG 2222
    • QBW251
    • Riociguat

The Route to Administration Insight

The market can be divided into oral and inhalation routes based on the administration method. The verbal course was responsible for the highest percentage of 63.7 percent in 2016 due to the advantages of its administration, such as accessibility and convenience without the assistance of a medical expert. The growing awareness of emerging economies of the benefits of oral medications that include CFTR inhibitors and pancreatic enzyme supplements is one of the main reasons driving sales of these medications.

Cystic Fibrosis Drug Market by Route of administration

Some approved therapeutics that can be administered orally include CFTR moderators like KALYDECO and ORKAMBI and pancreatic enzyme supplements like Creon/Zenpep, PERTZYE, Ultra, and Violence. A high level of commercialization and a massive demand for these medications for treating CF is predicted to propel the oral drug market. Based on the U.S. patient registry, 2015, Hypertonic saline was recommended for 21.5 percent of children between the ages of 0-3 years old and 41.9 percent of children in the age range of 3 to five years. The growing incidence of CF among infants is a significant reason for the increasing demand for oral formulations of drugs.

An increase in the number of clinical trials that grow the number of patients enrolled is among the primary factors that are expected to increase the market. Additionally, the Cystic fibrosis drug market is anticipated to develop with a high increase of 20.1 percent during the forecast time. An increasing amount of public and private companies investing in this sector is one of the factors that will boost the consumption of oral medications.

cystic fibrosis drug market

Customize this report as per your requirement

Regional insights of Cystic fibrosis Market Report

According to the geographic region, it is classified as North America, Europe, Asia Pacific, Latin America, Middle East & Africa. North America accounted for the most revenue, with USD 2,396.4 million in xxx. CF is prevalent within North America as most of those affected by CF have Caucasian descent. In addition, the efforts of the CF Foundation and Cystic Fibrosis Canada are among the primary reasons that can be the reason for its highest percentage.

But, Asia Pacific is expected to be the fastest-growing region with a high rise of 18.8 percent thus driving Cystic fibrosis Market size. While the prevalence of CF isn’t as frequently documented throughout the Asia Pacific area due to insufficient diagnosis and a lack of particular country-specific Cystic fibrosis patient registers, increasing awareness of CF diseases and treatments is anticipated to grow this segment’s growth during the forecast time. The region’s economic development and the improvement of health facilities are expected to increase the market during the forecast time.

The growing awareness among health professionals and patients about the latest therapeutics available in the market and their benefits over existing drugs is one of the significant factors expected to propel the market over the following years. Currently, the supply of specific medications for Cystic fibrosis is meager, but the increasing approvals and launches of new products in this area are expected to spur expansion.

Strategic Insights

The major players of Cystic fibrosis drug market are constantly engaged in creating new or combination products for treating cystic fibrosis. Investment in R&D is among the most effective strategies to outdo the market. The leading players in the Cystic fibrosis drug market report include: AbbVie, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Trikafta ; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alexia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan; and AstraZeneca. 

Detailed Analysis of  all major major players such as Abbvie cystic fibrosis market and AbbVie cystic fibrosis data will be covered in the study along with others.

Report Scope

AttributeInformation
The year of the base year used to estimate2021
Actual estimates/Historical data2016- 2021
Forecast period2022 – 2030
Cystic fibrosis Market Share representationRevenues In USD million and CAGR from 2022 through 2030.
Regional applicationNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country’s coverageU.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa
Report coverageForecast of revenue, share of company market landscape and growth drivers and the latest trends

cystic fibrosis drug market

Interested in Any Specific Region or Country Level Data?

Segments of Cystic fibrosis Market:

 

  • Class Outlook for Drug Class Outlook 
    • CFTR modulators
    • Mucolytics
    • Supplements to pancreatic enzymes
    • Bronchodilators
  • Route of Administration Outlook 
    • Oral drugs
    • Inhaled drugs
  • Regional Outlook 
  • North America
  • Europe
      • Germany
    • UK
  • Asia Pacific
      • China
    • Japan
  • Latin America
      • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
Research Approach/Methodology

MWR’s research methodology is based on extensive use of secondary and primary data sources. The research involves the analysis of various aspects impacting the industry, including the policies of the government, the competitive landscape, the market environment and historical data, as well as current developments in the market technological innovation, emerging technologies, and the advancement of technology in related industries, and potential market risks as well as market barriers and issues.

Market Size Estimation of Cystic fibrosis drug market

Bottom-up and top-down approaches are employed to verify the CF Market size and to estimate the size of the Cystic fibrosis drug market for companies’ regions, regions segment as well as product segments and applications (end users). The market estimates are built on the product’s retail price (excluding discounts offered by the distributor, manufacturer, wholesaler, trader, or).

Partially splits, market shares and breakdown of product segments are calculated based on the weights allocated to each segment based on their usage rate and average sale price. The regional splits of the total product market and sub-segments are determined by the per cent of adoption or use of the particular product within the specific region or country.

Top key players of  Cystic fibrosis drug market is determined through secondary data, and the market revenue is determined by secondary and primary approach. Secondary research comprised the study of financial and annual reports of the largest companies. In contrast, primary research involved extensive interviews with opinion makers and experts in the industry like experienced front-line employees, directors, CEOs, and marketing managers.

The market share, percentage splits and Growth Rate, as well as the market structure of the Cystic fibrosis drug market, are calculated from secondary sources and then verified by primary sources. All potential factors that affect the markets are verified by conducting primary analysis, and then analyzed to obtain the final qualitative and quantitative results.

Market Breakdown, Data and Triangulation of Cystic fibrosis drug market

After completing market engineering, including calculations of market statistics, size estimations, forecasting of market breakdown, and data triangulation, a lot of analysis are then conducted to collect details and to confirm the numbers to be verified.

Throughout the entire method of market engineering, top-down and bottom-up methods are were widely used, together with a variety of triangulation techniques for market estimation and forecasting of market trends for the entire market segment and sub-segments . A thorough analysis of quantitative data is also carried out using all the data gathered during the entire market engineering process to present important information throughout the research.

Data Sources of Cystic fibrosis drug market

Secondary Sources

Secondary sources include annual reports, press releases, non-profit organizations and industry associations, government agencies, customs information, and others. This study focuses on extensive use of secondary sources, directories, databases, and directories like Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones and Company) and trading ECONOMICS and News Network, Statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS and company house documents CAS (American Chemical Society) and investor presentations along with SEC filings of corporations.

Secondary research are utilized to discover and gather details that could be used for a thorough technological, market-oriented and commercial analysis of the product market. It also helps collecting necessary information on the most prominent companies, market classification and segmentation by market trends from the lowest level, and critical technological and market developments.

Primary Sources

For the research process, different sources from both the demand and supply sides are being interviewed to collect quantitative and qualitative information. The primary sources on the supply side comprise companies (and their rivals) and opinion leaders, experts from the industry and research institutes, distributors, traders and dealers, raw material suppliers and producers, etc.

The primary sources for demand-side information are industry experts, such as business leaders, sales and marketing directors, directors of innovation and technology supply chain executives, the market (product buyers) and top executives from a variety of key organizations and companies operating globally.

The primary studies are then conducted to find segments, types of segmentation, price ranges, application of the product important company, raw materials supply and demand downstream as well as the status of the industry and its forecast, and the fundamental market dynamics, such as risk factors, influence factors and opportunities obstacles to market entry, trends in the industry, and the strategies of key players.

COVID-19 impact Analysis of Cystic fibrosis drug market

To understand the impact of COVID on the Cystic fibrosis drug market, we must understand the supply chain of the Cystic fibrosis drug market industry and the value chain. By analysing the supply chain, we understand the bottlenecks affecting the industry’s growth. And by analysing the value chain, we understand what value each component adds to the entire industry. We then try to understand the COVID impact has on the industry by trying to find answers to the following questions: 

How many jobs have been lost?

How many people have died due to COVID?

How did the Government respond, and what measures Government has taken to revive a Cystic fibrosis drug market industry?

How companies in the Cystic fibrosis drug market have responded to COVID?

What growth rate companies are expecting in the Cystic fibrosis drug market?

We also analyse their annual reports and press releases to understand their
strategies post COVID. Then we move towards the primary research part and contact government officials and industry experts such as CEOs, COOs, Directors, VPs, Directors and Managers to understand what impact COVID has had on their businesses and what they are doing to cope with it.

We also try to understand their views regarding other financial aspects, such as recovery and obstacles in achieving pre-COVID growth and when they expect to achieve it.

Finally, after gathering the info from secondary and primary research, we try to form a model through which we gauge the COVID impact on a particular industry (Cystic fibrosis drug market).

Other MWR Trending Reports

Calcium sulfite Market

Positive Displacement Pump Market

Table of Content

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends & Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis – Porter’s
3.5. Cystic Fibrosis Therapeutics Market-SWOT Analysis, By Factor (Political & Legal, Economic and Technological), 2015
Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Cystic Fibrosis Therapeutics Market Share by Drug Class, 2016 & 2025 (USD Million)
4.2. Pancreatic Enzyme Supplements
4.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.3. Mucolytics
4.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.4. Bronchodilators
4.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
4.5. CFTR Modulators
4.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Estimates & Trend Analysis
5.1. Cystic Fibrosis Therapeutics Market Share by Route of Administration, 2016 & 2025 (USD Million)
5.2. Oral Drugs
5.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
5.3. Inhaled Drugs
5.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
Chapter 6. Cystic Fibrosis Therapeutics Market: Regional Outlook, by Drug Class and Route of Administration
6.1. Cystic Fibrosis Therapeutics Market Shares by Region, 2016 & 2025 (USD Million)
6.2. North America
6.2.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.2.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.2.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.2.4. The U.S.
6.2.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.2.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.2.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.2.5. Canada
6.2.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.2.5.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.2.5.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.3. Europe
6.3.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.3.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.3.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.3.4. Germany
6.3.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.3.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.3.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.3.5. UK
6.3.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.3.5.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.3.5.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.4. Asia Pacific
6.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.4.4. China
6.4.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.4.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.4.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.4.5. Japan
6.4.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.4.5.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.4.5.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.5. Latin America
6.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.5.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.5.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.5.4. Brazil
6.5.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.5.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.5.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.5.5. Mexico
6.5.5.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.5.5.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.5.5.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.6. Middle East & Africa
6.6.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.6.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.6.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
6.6.4. South Africa
6.6.4.1. Market estimates and forecast, 2014 – 2025 (USD Million)
6.6.4.2. Market estimates and forecast by drug class, 2014 – 2025 (USD Million)
6.6.4.3. Market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
Chapter 7. Competitive Landscape
7.1. Strategic Framework
7.2. Company Profiles
7.2.1. AbbVie Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. F. Hoffmann-La Roche Ltd
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Gilead
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Novartis AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Vertex Pharmaceuticals Incorporated
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. AIT (Advanced Inhalation Therapies)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Alaxia
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Teva Pharmaceutical Industries Ltd.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Merck & Co. Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Alcresta Therapeutics, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. ALLERGAN
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. AstraZeneca
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives

 

List of Tables

TABLE 1 North America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 2 North America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 3 U.S. cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 4 U.S. cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 5 Canada cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 6 Canada cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 7 Europe cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 8 Europe cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 9 Germany cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 10 Germany cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 11 UK cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 12 UK cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 13 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 14 Asia Pacific cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 15 China cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 16 China cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 17 Japan cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 18 Japan cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 19 Latin America cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 20 Latin America cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 21 Mexico cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 22 Mexico cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 23 Brazil cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 24 Brazil cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 25 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 26 Middle East and Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)
TABLE 27 South Africa cystic fibrosis therapeutics market estimates and forecast by drug class, 2014 – 2025 (USD Million)
TABLE 28 South Africa cystic fibrosis therapeutics market estimates and forecast by route of administration, 2014 – 2025 (USD Million)

 

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Cystic fibrosis therapeutics market, Heat Map Analysis
FIG. 13 Cystic fibrosis therapeutics market drug class outlook key takeaways
FIG. 14 Cystic fibrosis therapeutics market: drug class movement analysis
FIG. 15 Pancreatic enzyme supplements market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 16 Mucolytics market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 17 Bronchodilators market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 18 CFTR modulators market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 19 Cystic fibrosis therapeutics market route of administration outlook key takeaways
FIG. 20 Cystic fibrosis therapeutics market: route of administration movement analysis
FIG. 21 Oral drugs market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 22 Inhaled drugs market estimates and forecast, 2014 – 2025 (USD Million)
FIG. 23 Cystic fibrosis therapeutics market Regional outlook, 2016 & 2025
FIG. 24 North America cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 25 U.S. cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 26 Canada cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 27 Europe cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 28 Germany cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 29 UK cystic fibrosis therapeutics market estimates and forecasts, 2014 – 2025 (USD Million)
FIG. 30 Asia Pacific cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 31 China cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 32 Japan cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 33 Latin America cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 34 Brazil cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 35 Mexico cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 36 MEA cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 37 South Africa cystic fibrosis therapeutics market estimates and forecasts, 2013 – 2024 (USD Million)
FIG. 38 Competitive strategy adopted by leading players

 

Segmentation

  • Class Outlook for Drug Class Outlook 
    • CFTR modulators
    • Mucolytics
    • Supplements to pancreatic enzymes
    • Bronchodilators
  • Route of Administration Outlook 
    • Oral drugs
    • Inhaled drugs
  • Regional Outlook 
  • North America
  • Europe
      • Germany
    • UK
  • Asia Pacific
      • China
    • Japan
  • Latin America
      • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Major Companies

AbbVie, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Trikafta ; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alexia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan; and AstraZeneca. 

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF